Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

The positive top-line results for Merck & Co's cardiovascular outcomes trial for its CETP inhibitor anacetrapib may not be enough to de-risk the class, and questions remain about the level of clinical benefit and the regulatory options.